About the bill
- Full Title
A bill to provide for the expedited development and evaluation of drugs designated as breakthrough drugs.
The bill’s title was written by its sponsor.
This is the first step in the legislative process.
2 cosponsors (2R) (show)
- Committee Assignments
The committee chair determines whether a bill will move past the committee stage.
There have been no roll call votes related to this bill.
- Subject Areas
- Related Bills
Legislative action may be ocurring on one of these bills in lieu of or in parallel to action on this bill.S. 3187 (Related)Food and Drug Administration Safety and Innovation Act
Enacted — Signed by the President
Jul 9, 2012S. 2516 (Related)Food and Drug Administration Safety and Innovation Act
Reported by Committee
Last Action: May 7, 2012
Search for similar bills.
Links & tools
Click a format for a citation suggestion:
Civic Impulse. (2016). S. 2236 — 112th Congress: Advancing Breakthrough Therapies for Patients Act of 2012. Retrieved from https://www.govtrack.us/congress/bills/112/s2236
“S. 2236 — 112th Congress: Advancing Breakthrough Therapies for Patients Act of 2012.” www.GovTrack.us. 2012. July 24, 2016 <https://www.govtrack.us/congress/bills/112/s2236>
|title=S. 2236 (112th)
|accessdate=July 24, 2016
|author=112th Congress (2012)
|date=March 26, 2012
|quote=Advancing Breakthrough Therapies for Patients Act of 2012